1 Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India 110029.
2 Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
AJR Am J Roentgenol. 2019 Aug;213(2):275-285. doi: 10.2214/AJR.18.20845. Epub 2019 Apr 17.
Several clinical studies have shown the efficacy of Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) for metastatic castration-resistant prostate cancer (mCRPC). The purpose of this article is to present results of a systematic review and meta-analysis aimed at compiling and outlining efficacy and safety data on Lu-PSMA RLT for mCRPC across all studies published to date. The results of the systematic review and meta-analysis suggest that Lu-PSMA RLT is an effective treatment of advanced-stage mCRPC that is refractory to standard therapeutic options and that it has a low toxicity profile. High-level evidence from randomized control trials is crucial for confirming the effectiveness of Lu-PSMA RLT and for instituting this therapy in the routine clinical care of patients with mCRPC.
几项临床研究表明，Lu 标记的前列腺特异性膜抗原（PSMA）放射性配体治疗（RLT）对转移性去势抵抗性前列腺癌（mCRPC）有效。本文的目的是呈现一项系统评价和荟萃分析的结果，旨在编译和概述迄今为止发表的所有研究中关于 Lu-PSMA RLT 治疗 mCRPC 的疗效和安全性数据。系统评价和荟萃分析的结果表明，Lu-PSMA RLT 是一种有效的治疗方法，适用于对标准治疗方案耐药的晚期 mCRPC，且具有较低的毒性特征。来自随机对照试验的高级别证据对于证实 Lu-PSMA RLT 的有效性以及将该疗法纳入 mCRPC 患者的常规临床治疗至关重要。
